Edition:
India

Alexion Pharmaceuticals Q2 Non-GAAP Earnings Per Share $2.64


Wednesday, 24 Jul 2019 

Alexion Pharmaceuticals Inc ::ALEXION REPORTS SECOND QUARTER 2019 RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $2.64.Q2 GAAP EARNINGS PER SHARE $2.04.Q2 REVENUE $1.203 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.17 BILLION.Q2 EARNINGS PER SHARE ESTIMATE $2.34 -- REFINITIV IBES DATA.ALEXION PLANS TO FILE FOR REGULATORY APPROVALS IN EU AND JAPAN IN SECOND HALF OF 2019.PLANS TO INITIATE A PHASE 3 STUDY OF ULTOMIRIS IN NMOSD BY END OF 2019, PENDING REGULATORY FEEDBACK.INCREASING FY TOTAL REVENUES AND EPS GUIDANCE.ALEXION PHARMACEUTICALS - DOSING IS UNDERWAY IN A SINGLE, PK-BASED PHASE 3 STUDY OF ULTOMIRIS, DATA ARE EXPECTED IN EARLY 2020.SEES FY TOTAL REVENUES $4,750 MILLION TO $4,800 MILLION.PLANS TO INITIATE A PHASE 3 STUDY OF ULTOMIRIS IN HSCT-TMA IN FIRST HALF OF 2020, PENDING REGULATORY FEEDBACK.SEES FY EARNINGS PER SHARE $8.13 TO $8.41.SEES FY ADJUSTED EARNINGS PER SHARE $9.65 TO $9.85.FY2019 EARNINGS PER SHARE VIEW $9.44, REVENUE VIEW $4.78 BILLION -- REFINITIV IBES DATA.